MHRA Prohibits Over-The-Counter Sale Of Oral Diclofenac Drug Alert Following Concerns Regarding Cardiac Side Effect Risk 19.01.2015 The Medicines and Healthcare products Regulatory Agency (MHRA) has issued alert restricting the sale of the painkiller Diclofenac to a prescription-only basis. The class 2 drug alert applies to Voltarol Pain-Eze, Pain-Eze extra strength 25mg and Joint Pain 12.5mg tablets, which are manufactured by Novartis Consumer Health UK Limited. In addition, other products affected are First Resort Double action Pain Relief 12.5mg and Boots Joint Pain relief 12.5 tablets, both manufactured by Actavis Group. The decision to remove such products from sale follows studies which identified an increased risk of serious cardiac side effect in some patients, particularly if used at high doses and for long term treatment. The MHRA has advised that patients who have bought the affected products should speak to pharmacists regarding potential alternatives, while those prescribed Diclofenac should continue to take the medicine as their medical history will already have been assessed. Tags Personal Injury Product Liability Medical Negligence David Body Sheffield Related articles 20.09.2017Mental Health Trust Pays Damages To Family Of Vulnerable Man Who Died In High Rise Fire 20.09.2017Landmark Legal Ruling Will Allow Doctors to Withdraw Treatment To Those Suffering Debilitating Diseases if Families Agree 20.09.2017Inquest Finds Alzheimer Suffer Died Due To Ingesting Chlorine Tablets 19.09.2017Two Women Instruct Lawyers After Being Abused By Dr Philip Schuppler 19.09.2017Specialist Public Health Lawyers Instructed After Dry Ice Cocktail Drank at The Alchemist ‘Leaves Man With Severe Stomach Burns'